Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
Status:
Completed
Trial end date:
2021-01-04
Target enrollment:
Participant gender:
Summary
The goal of this single-center, open-labelled, clinical trial in two groups aims to proof
that a specific group of antibiotics (carbapenems) can be used to treat pulmonary
tuberculosis if it is combined with another antibiotic (amoxicillin/clavulanate). A total of
113 male or female participants (8 groups and 9 treatment regimens as group 8 was split into
2 groups of 4 participants receiving Rifafour e-275), aged between 18 and 65 years
(inclusive), with newly diagnosed, smear-positive, pulmonary TB.